000			02155 a2200577 4500
005			20250516145004.0
264		0	_c20130916
008			201309s 0 0 eng d
022			_a1097-0142
024	7		_a10.1002/cncr.28113 _2doi
040			_aNLM _beng _cNLM
100	1		_aKantarjian, Hagop M
245	0	0	_aStage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia. _h[electronic resource]
260			_bCancer _cJul 2013
300			_a2611-9 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntimetabolites, Antineoplastic _xtherapeutic use
650	0	4	_aAntineoplastic Agents _xadministration & dosage
650	0	4	_aAurora Kinase B
650	0	4	_aAurora Kinases
650	0	4	_aCytarabine _xadministration & dosage
650	0	4	_aDrug Administration Schedule
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aKaplan-Meier Estimate
650	0	4	_aLeukemia, Myeloid, Acute _xdrug therapy
650	0	4	_aMale
650	0	4	_aNeutropenia _xchemically induced
650	0	4	_aOrganophosphates _xadministration & dosage
650	0	4	_aProtein Serine-Threonine Kinases _xantagonists & inhibitors
650	0	4	_aQuinazolines _xadministration & dosage
650	0	4	_aStomatitis _xchemically induced
650	0	4	_aTreatment Outcome
700	1		_aMartinelli, Giovanni
700	1		_aJabbour, Elias J
700	1		_aQuintás-Cardama, Alfonso
700	1		_aAndo, Kiyoshi
700	1		_aBay, Jacques-Olivier
700	1		_aWei, Andrew
700	1		_aGröpper, Stefanie
700	1		_aPapayannidis, Cristina
700	1		_aOwen, Kate
700	1		_aPike, Laura
700	1		_aSchmitt, Nicola
700	1		_aStockman, Paul K
700	1		_aGiagounidis, Aristoteles
773	0		_tCancer _gvol. 119 _gno. 14 _gp. 2611-9
856	4	0	_uhttps://doi.org/10.1002/cncr.28113 _zAvailable from publisher's website
999			_c22688541 _d22688541